Investors Encouraged to Join Class Action Against Sage Therapeutics
Levi & Korsinsky, LLP is reaching out to those who invested in Sage Therapeutics, Inc. (NASDAQ: SAGE) regarding a class action securities lawsuit. This legal action seeks justice for shareholders who have experienced financial losses due to alleged fraudulent activities by the company.
Understanding the Class Action
The class action lawsuit is designed to recover losses for investors adversely affected between specific dates. The allegations involve significant claims regarding misrepresentation and misleading statements made by Sage Therapeutics about its drug efficacy and regulatory approvals.
Details of the Allegations
The filed complaint points out that there were numerous instances of alleged securities fraud. Notably, the statements about Zuranolone, a key treatment for postpartum depression, were said to be misleading. Investors were led to believe it would be effective in treating Major Depressive Disorder (MDD), but evidence suggested otherwise. Furthermore, approval from the FDA for Zuranolone’s use in MDD was called into question due to these inaccuracies.
Moreover, the claims extend to other treatments such as SAGE-718 and SAGE-324. Allegations have been made suggesting that their effectiveness in treating Mild Cognitive Impairment (MCI) due to Parkinson's Disease and essential tremor were overstated. Such assertions lead to doubts about the overall prospects of these drugs and damaged confidence in the company's public statements.
The Path Forward for Affected Investors
If you are a Sage Therapeutics investor and have suffered losses during the relevant timeline, it is crucial to act quickly. You have until a specified date to request that the Court appoint you as a lead plaintiff, which can facilitate your involvement in the lawsuit. However, participating does not require you to serve as a lead plaintiff, and there are no costs associated with joining the class.
No Financial Burden for Participants
It is important for investors to know that there is no financial obligation to engage with this class action. Members have the potential to receive compensation even without any upfront costs, ensuring that participation is devoid of financial strain.
Why Choose Levi & Korsinsky?
The firm of Levi & Korsinsky boasts a strong track record over the past two decades, securing hundreds of millions of dollars for shareholders. Their expertise in complex securities litigation is backed by a capable team of more than 70 professionals. Recognized as one of the top firms in the United States, they have consistently ranked highly in securities litigation.
Contact Information
For further information, affected investors can reach out to Joseph E. Levi, Esq., or Ed Korsinsky, Esq. at Levi & Korsinsky, LLP. They are available for inquiries and can provide assistance regarding the ongoing class action lawsuit against Sage Therapeutics.
Frequently Asked Questions
What should I do if I lost money investing in Sage Therapeutics?
If you incurred financial losses, consider joining the class action lawsuit initiated by Levi & Korsinsky, LLP to seek potential compensation.
What are the allegations against Sage Therapeutics?
The company is accused of making false statements related to the effectiveness and approval prospects of its drugs, leading investors to hold a misleading view of their investments.
Is there any cost to join the class action?
No, there are no out-of-pocket costs for participants in the class action lawsuit.
When do I need to act by if I want to participate?
You should request to be appointed as a lead plaintiff by a specified deadline to ensure your place in the lawsuit.
How can I reach out for more information?
Affected investors can contact the firm directly via email or phone for guidance and information on how to proceed.
